François Maisonrouge, MS, MBA

François Maisonrouge, MS, MBA, is a senior managing director in Evercore’s strategic advisory business. He has spent his whole career, starting in the eighties, giving strategic advice to health care companies in connection with their mergers and acquisitions, and fund raising activities. More recently, at Evercore, among other transactions, François was involved in advising Arena Pharmaceuticals on its sale to Pfizer; Novo Nordisk on its acquisition of Dicerna Pharmaceuticals; Parexel on its sale to EQT; AstraZeneca on its acquisition of Alexion; Sanofi on its acquisition of Principia; Nestlé on its sale of Nestlé Skin Health to EQT and ADIA; Bristol-Myers Squibb on its acquisition of Celgene; Takeda on its acquisition of Shire; AstraZeneca on its defense across from Pfizer; and Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories from Daiichi-Sankyo.

In addition, François has been involved in numerous other merger and acquisition transactions and initial public offerings and follow-on equity offerings, principally for biotech companies, as well as structured capital raising transactions.

Prior to joining Evercore, François was a managing director and chairman of life sciences at Credit Suisse, where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology.

He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and the chairman of the Pasteur Foundation. In 2014, François was awarded the rank of Chevalier de la Légion d’Honneur.

François holds an MS in engineering from Ecole Centrale de Lyon and an MBA from Harvard Business School.